DMRA · Damora Therapeutics, Inc.
$21.08
+0.52 (+2.53%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.31B
Shares
61.74M
Volume · Oct 9
368.73K
Avg daily vol (3M)
529.45K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.08
Open$20.53
Day$20.44–21.86
52W close$4.95–34.14
Avg vol 30d715K
Short int4.7M · 7.7% float · 4.8d
Short vol81%
DataOct 2020–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$262.83M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
2.7
Trailing earnings · reciprocal yield 36.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4,521.1%
Year over year · more shares
Price change (1Y)
+93.1%
Trailing year
Short interest
7.7%
Latest settlement · 4.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−21%
below
RSI (14)
39
neutral
MACD trend
Positive
52-week position
55%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
−20%
trailing
YTD return
−8%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
2 of 104 funds reported for Sep 30 · net +131 sh shares · +2 new
Insider flow
Accumulating
Net +$252.9K over 90 days · 0% sells
Short interest
Rising
7.67% of float · ▲ +0.0% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
104 holders — near 2-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
EPS growth
+121%
Y/Y
Free cash flow
$-6.9M
Quant / Vol
risk profile
Volatility
273%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
39
Neutral
MACD trend
Positive
Bullish
52-week position
55%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $27 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
2 of 104 funds reported for Sep 30 · net +131 sh shares · +2 new
Insider flow
Accumulating
Net +$252.9K over 90 days · 0% sells
Short interest
Rising
7.67% of float · ▲ +0.0% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
104 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $21 · 55%
Range high $34
vs 200-day avg -19%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMRA
this stock
Damora Therapeutics, Inc.
|
$1.31B | -8.4% | — | — | 7.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +12.5% | +46.2% | 29.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.58B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMRA | +2.1% | -25.0% | -20.2% | -0.9% | -8.4% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | +0.9% | -26.9% | -30.1% | -3.0% | -22.6% |